Mestinon

Pyridostigmine bromide, the active ingredient in Mestinon, is an acetylcholinesterase inhibitor presented as a tablet for oral use. It is employed to improve muscle strength in patients with myasthenia gravis, a chronic autoimmune disorder that causes fluctuating skeletal‑muscle weakness. It works by increasing the availability of acetylcholine at the neuromuscular junction, thereby enhancing transmission of nerve impulses to skeletal muscles.

GNH USA supplies Mestinon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets.

Mestinon (pyridostigmine bromide) is used in the management of neuromuscular transmission disorders, primarily myasthenia gravis. - Generalized myasthenia gravis: enhances overall muscle strength and reduces daily fatigue. - Ocular myasthenia gravis: improves eye muscle control, reducing ptosis and diplopia. - Myasthenic crisis (post‑operative or severe exacerbation): provides symptomatic relief while definitive therapies take effect.

Pyridostigmine bromide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: upset stomach often occurring after the first doses. - Diarrhea: loose stools that may be mild to moderate. - Abdominal cramps: discomfort in the stomach region. - Increased salivation: excess saliva production. - Sweating: heightened perspiration. - Muscle cramps: involuntary tightening of muscles.

Serious or Rare Side Effects: - Bradycardia: abnormally slow heart rate that may require monitoring. - Severe bronchospasm: sudden narrowing of airways, especially in asthmatic patients. - Allergic reactions: rash, itching, angioedema, or anaphylaxis. - Paradoxical muscle weakness: worsening of weakness despite therapy. - Seizures: rare neurologic events requiring immediate medical attention.

When prescribing pyridostigmine bromide, clinicians should consider several safety precautions to minimize risk. - Renal impairment: adjust dose because the drug is excreted unchanged in urine. - Asthma or COPD: monitor for bronchospasm due to cholinergic effects. - Cardiac disease: observe for bradyarrhythmias or conduction abnormalities. - Concomitant anticholinergic drugs: may reduce therapeutic effect. - Pregnancy and lactation: use only if benefit outweighs potential risk (category unknown). - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Pyridostigmine bromide can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Beta‑blockers: may exacerbate bradycardia. - Succinylcholine: prolonged neuromuscular blockade. - Aminoglycoside antibiotics (e.g., gentamicin): may worsen neuromuscular weakness.

Moderate Interactions (Monitor Closely): - Anticholinergic agents (e.g., atropine): reduce drug effect. - Diuretics (e.g., furosemide): increase risk of hypokalemia, enhancing muscle cramps. - Muscle relaxants (e.g., dantrolene): may diminish therapeutic response.